Main description:

This book provides an overview of the latest
developments in the concepts and management of ovarian cancer. The new data
presented throughout opens the way to radically different therapeutic
approaches. Surgery remains the core of ovarian cancer treatment, but its
ultimate goal and the standard surgical procedure have evolved, giving rise to
the question of how to label expert centers for debulking surgery. Neo-adjuvant
chemotherapy is becoming more popular and is also a new field for testing novel
drug combinations.

Over recent years, ovarian cancer management
has embraced molecular biology. It is now more correct to talk about cancers of
the ovary rather than ovarian cancer, since it is not a unique disease but
several entities with different molecular drivers. The significant advances in
drugs targeting the microenvironment or the tumor cell DNA repair mechanisms
are presented in detail together with exciting future perspectives.

All these advances would not have been possible
without collaborative groups such as the GINECO group in France and their
integration in wider clinical research networks at the European (ENGOT) and
international (GCIG) level.

Contents:

PART 1: OVARIAN CANCER MANAGEMENTChapter 1. Clinical research in Europe dedicated to ovarian cancersE. Pujade-Lauraine, Paris, France
Chapter 2. Genetics of ovarian carcinomasClaire Senechal, Bruno Buecher, Antoine de Pauw, Claude Houdayer, Etienne Rouleau, Catherine Nogues, Dominique Stoppa-Lyonnet
Chapter 3. Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality Fabrice Lecuru, Charlotte Ngo, Anne Sophie Bats, Cherazade Bensaid, Pierre Combe, Eric Pujade Lauraine, Marie Aude le Frere Belda, Laure Fournier
Chapter 4. How to evaluate tumor burden before therapeutic decisionA. Fagotti, L. Pedone Anchora, M. Pacciani, G. Scambia
Chapter 5. Value of lymphadenectomyPhilipp Harter, Florian Heitz, Andreas du Bois
Chapter 6. HYPEC: what is the evidence? Jean-Marc Classe
Chapter 7. Onco-fertility applied to ovarian cancers
Enrica Bentivegna, Sebastien Gouy, Catherine Uzan, Marcos Ballester, Catherine Poirot, Emile Darai, Philippe Morice
Chapter 8. First-line systemic therapy (chemo/antiangiogenics) Sandro Pignata, Sabrina Cecere
Chapter 9.Elderly C. Falandry, Lyon, France
Chapter 10. Treatment at relapse (surgery & Systemic treatments)J. Pfisterer, A. Floquet
Chapter 11. The future in ovarian cancers & place of the new immunotherapies in ovarian cancersHolbrook E.K. Kohrt , Amani Makkouk, Cariad Chester
PART 2: PARTICULAR TYPES OF OVARIAN CANCERS (for each: histology and molecular specificities, specificity for surgery and management in first line and relapse)

Chapter 12. High Grade Carcinomas, BRCA mutations and the role of PARP inhibitorsJonathan A Ledermann
Chapter 13. Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or PeritoneumDavid M. Gershenson
Chapter 14. Clear Cell carcinomaMasashi Takano, Satoshi Takakura, Keiichii Fujiwara
Chapter 15. Endometrioid carcinoma Laure de Cock, Gerlinde Averous, Philippe Barthelemy, Jean-Emmanuel Kurtz
Chapter 16. Mucinous carcinomaJubilee Brown, MD Anderson
Chapter 17. Uterine and Ovarian CarcinosarcomaD. Berton-Rigaud, JS Frenel, I Ray-Coquard
Chapter 18. Malignant Ovarian Germ Cell Tumours; an overview of management and controversiesDr Costi Alifrangis, Professor Michael J Seckl
Garbi Annalisa, Achilarre Maria Teresa, Colombo Nicoletta
Chapter 20. Very rare ovarian malignant tumors including small cell carcinoma Patricia Pautier